
Erastin
CAS No. 571203-78-6
Erastin( Erastin )
Catalog No. M15083 CAS No. 571203-78-6
Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 87 | In Stock |
![]() ![]() |
10MG | 122 | In Stock |
![]() ![]() |
25MG | 206 | In Stock |
![]() ![]() |
50MG | 311 | In Stock |
![]() ![]() |
100MG | Get Quote | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameErastin
-
NoteResearch use only, not for human use.
-
Brief DescriptionErastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS.
-
DescriptionErastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS.(In Vitro):Erastin (10 μM; 24 h) triggers ferroptosis in ectopic endometrial stromal cells (EESCs), and increases the total ROS level at 9 h.Erastin shorts mitochondria and increases membrane density in EESCs.Erastin (10 μM; 9 h) decreases the mRNA expression levels of iron-related proteins, such FPN (iron exporter) in EESCs. However, FPN overexpression significantly inhibits erastin-induced ferroptosis in EESCs.Erastin (10 μM; 24 h) induces mitochondrial permeability transition pore (mPTP) opening in HT-29 colorectal cancer cells.Erastin (30 μM; 72 h) significantly inhibits the growth of HT-29 colorectal cancer cells.The molecular mechanism by which Erastin induces ferroptosis is related to genes regulating iron or mitochondrial fatty acid metabolism. Includes ribosomal protein L8, iron response element binding protein 2 (IREB2), ATP synthase F0 complex subunit C3, citrate synthase, tetrapeptide repeat domain 35, and acyl-CoA synthetase family member 2 (ACSF2).(In Vivo):Erastin (40 mg/kg; i.p.; once every 3 days for 2 weeks) suppresses endometriotic implants in the mouse endometriosis model, indicating Erastin regresses ectopic lesions by trigging ferroptosis.Erastin (10 mg/kg, 30 mg/kg; i.p.; once daily.
-
In VitroCell Viability Assay Cell Line:Normal endometrial stromal cells (NESCs) and endometrial stromal cells (EESCs)Concentration:0, 0.5, 0.8, 1, 1.5, 2, 2.5, 5, 10?μM Incubation Time:24 hours Result:Induced cell detachment and overt death in EESCs, but not NESCs.Apoptosis AnalysisCell Line:EESCs infected with adenovirus expressing FPN cDNA (co-incubation for 24 hr)Concentration:0, 0.5, 1.5, 2.5, 5 and 2.5?μM Incubation Time:24 hours Result:Induced ferroptosis by decreasing the levels of total ROS and lipid ROS. And reversed by the overexpression of FPN in adenovirus-infected cells.
-
In VivoAnimal Model:Mouse model of endometriosisDosage:40 mg/kg Administration:Intraperitoneal injection; once every 3 days for 2 weeksResult:Showed little impact on body weight of mice and hair of mice displayed neat and glossy.
-
SynonymsErastin
-
PathwayApoptosis
-
TargetFerroptosis
-
RecptorFerroptosis
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number571203-78-6
-
Formula Weight547.04
-
Molecular FormulaC30H31ClN4O4
-
Purity>98% (HPLC)
-
SolubilityDMSO: 19 mg/mL (34.73 mM)
-
SMILESO=C1N(C2=CC=CC=C2OCC)C(C(N3CCN(C(COC4=CC=C(Cl)C=C4)=O)CC3)C)=NC5=C1C=CC=C5
-
Chemical Name2-(1-(4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)ethyl)-3-(2-ethoxyphenyl)quinazolin-4(3H)-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Dolma S, et al. Y Cell. 2003, 3(3), 285-296.
molnova catalog



related products
-
UAMC-3203
UAMC-3203 is a novel potent, drug-like ferroptosis inhibitor with IC50 of 12 nM.
-
ROS-generating?agent...
Ros-generating agent 1 has anticancer activity and generates ROS by covalently modifying Sec-498 residues of TrxR.
-
Ferrostatin-1
Ferrostatin-1 is a potent ferroptosis inhibitor with IC50 of 33 nM.